Biologika und Immunglobuline für die Therapie des Pyoderma gangraenosum – Analyse von 52 Patienten

Vor dem Hintergrund häufiger Nebenwirkungen und Therapieversager unter Glukokortikosteroiden (GCS) und Ciclosporin (CSA) bei Pyoderma gangraenosum (PG), war das Ziel der vorliegenden Arbeit eine Analyse der Wirksamkeit und Sicherheit von Biologika und intravenösen Immunglobulinen (IVIG).

[1]  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial , 2017, British Medical Journal.

[2]  J. Klode,et al.  Patients with pyoderma gangrenosum – analyses of the German DRG data from 2012 , 2016, International wound journal.

[3]  M. Augustin,et al.  Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients , 2016, The British journal of dermatology.

[4]  P. Quaglino,et al.  The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum , 2015, The British journal of dermatology.

[5]  E. Maverakis,et al.  Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. , 2015, Acta dermato-venereologica.

[6]  John M Cafardi,et al.  Intravenous Immunoglobulin as Salvage Therapy in Refractory Pyoderma Gangrenosum: Report of a Case and Review of the Literature , 2014, Case Reports in Dermatology.

[7]  M. Ye,et al.  Pyoderma Gangrenosum: A Review of Clinical Features and Outcomes of 23 Cases Requiring Inpatient Management , 2014, Dermatology research and practice.

[8]  D. Fanoni,et al.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome , 2014, Clinical and experimental immunology.

[9]  J. Klode,et al.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients , 2013, Orphanet Journal of Rare Diseases.

[10]  J. Andrews,et al.  Systematic review: IBD‐associated pyoderma gangrenosum in the biologic era, the response to therapy , 2013, Alimentary pharmacology & therapeutics.

[11]  T. Lobaton,et al.  Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease , 2013, Digestive Diseases and Sciences.

[12]  A. Qureshi,et al.  Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients , 2011, The British journal of dermatology.

[13]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[14]  D. Kastner,et al.  Autoinflammatory Disease Reloaded: A Clinical Perspective , 2010, Cell.

[15]  N. Kang,et al.  Treatment of pyoderma gangrenosum with the anti-TNFalpha drug - Etanercept. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[16]  T. Gambichler,et al.  Intravenous immunoglobulin for pyoderma gangrenosum , 2008, The British journal of dermatology.

[17]  G. Anhalt,et al.  Treatment of pyoderma gangrenosum with intravenous immunoglobulin , 2007, The British journal of dermatology.

[18]  A. Qureshi,et al.  Adalimumab for treatment of pyoderma gangrenosum , 2007, The British journal of dermatology.

[19]  C. Probert,et al.  T‐cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking , 2007, The British journal of dermatology.

[20]  R. Kirsner,et al.  Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series , 2007, International journal of dermatology.

[21]  J. Reichrath,et al.  Pyoderma gangrenosum: Clinical presentation and outcome in 18 cases and review of the literature , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[22]  M. Friedrich,et al.  S3‐Leitlinie zur Therapie der Psoriasis vulgaris , 2006 .

[23]  A. Forbes,et al.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.

[24]  J. Reichrath,et al.  Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. , 2005, Journal of the American Academy of Dermatology.

[25]  R. Weenig,et al.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria , 2004, International journal of dermatology.

[26]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[27]  S. Chimenti,et al.  The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[28]  P. Driesch,et al.  Pyoderma gangrenosum: a report of 44 cases with follow‐up , 1997, The British journal of dermatology.

[29]  F. T. Veloso,et al.  Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. , 1996, Journal of clinical gastroenterology.

[30]  W. Su,et al.  Pyoderma gangrenosum: a review of 86 patients. , 1985, The Quarterly journal of medicine.

[31]  L. Brunsting,et al.  PYODERMA (ECHTHYMA) GANGRENOSUM: CLINICAL AND EXPERIMENTAL OBSERVATIONS IN FIVE CASES OCCURRING IN ADULTS , 1930 .